Almir Tavares

Dr. Almir Tavares

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2008 in Journal of Affective Disorders
Verified
Journal Article
Closed access
FVFernando Madalena Volpe
Fernando Madalena Volpe
ATAlmir Tavares
Almir Tavares
JPJosé Alberto Del Porto
José Alberto Del Porto

1 October 2012 in The Journal of Neuropsychiatry and Clinical Neurosciences
Verified
Journal Article
Closed access
PDF file
FVFernando Madalena Volpe
Fernando Madalena Volpe
ATAlmir Tavares
Almir Tavares

21 May 2019 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
WMWagner José Martorina
Wagner José Martorina
ATAlmir Tavares
Almir Tavares
Aims. Sleep duration (SD) has been associated with metabolic outcomes. Is there an independent association between short/long SD and glycemic control (GC) in type 2 diabetes mellitus (T2DM) outpatients, compared to intermediate SD? Employing up-to-date definitions of SD, we comprehensively considered, simultaneously, all known confounding/mediating factors that recently emerged in the literature: age, gender, diet, physical activity, obesity, night pain, nocturnal diuresis, sleep quality, chronotype, sleep apnea, depressive symptoms, alcohol, caffeine, tobacco, number of endocrinologist appointments, T2DM family history, and sleep medication.Methods. A cross-sectional study of 140 consecutive T2DM outpatients, ages 40-65,glycohemoglobin HbA1c goal≤7. We searched for variables (including HbA1c) significantly associated with short (8 hours) SD, in comparison to intermediate SD (6-8 hours).Results. Higher HbA1clevels increased the chance of belonging to the group that sleeps 8 hours (p<0.05).Conclusions. There is an independent association between short SD and elevated HbA1c, in real-world T2DM outpatients. Future interventional studies could evaluate weather consistent, long-term sleep extension, from <6 hours to 7–9 hours per 24 hours, improves GC in T2DM outpatients.

1 December 1993 in The British Journal of Psychiatry
Verified
Journal Article
Closed access
ATAlmir Tavares
Almir Tavares

10 August 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
WMWagner José Martorina
Wagner José Martorina
ATAlmir Tavares
Almir Tavares
Background: Glycemic variability in patients with type 2 diabetes mellitus (T2DM) may be associated with chronic complications of the disease. Melatonin is a hormone that plays a crucial role in biological rhythms. Previous studies have indicated that individuals with T2DM often exhibit reduced melatonin production. In this study, our objective was to investigate whether nighttime melatonin supplementation could mitigate glycemic variability in these patients. Methods: Crossover, double-blind, placebo-controlled, randomized study. A total of 30 patients were enrolled in this study. The study included 15 participants who followed the intervention sequence of placebo (7 days)—washout (7 days)—melatonin (3 mg) (7 days), and another 15 participants who followed the sequence of melatonin (3 mg) (7 days)—washout (7 days)—placebo (7 days). During the final three days of the first and third weeks, the participants measured their pre- and postprandial capillary blood glucose levels. This study was reported according to the CONSORT 2010 statement: extension to randomized crossover trials. Results: There was a significant absolute difference in the breakfast blood glucose levels (p = 0.016) on Day 7. The use of melatonin determined a greater positive variation between pre- and postprandial glycemia than the placebo. The difference in glycemic amplitude between post-dinner Day 6 and pre-breakfast Day 7 was also significantly higher in the melatonin group (p = 0.032). Conclusions: Melatonin increased glycemic variability in individuals with type 2 diabetes mellitus (T2DM). These results can be attributed to the residual daytime effects of melatonin, prospective proximal effects, and damage to the prospective distal effects of exogenous melatonin. Therefore, caution should be exercised when administering melatonin supplementation to patients with T2DM, taking into consideration factors such as dosage, duration of use and genetic considerations.

1 June 2003 in Brazilian Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
FVFernando Madalena Volpe
Fernando Madalena Volpe
ATAlmir Tavares
Almir Tavares
HCHumberto Correa
Humberto Correa
OBJECTIVE: To describe the clinical practices on the treatment of mania in a Brazilian hospital, and to compare them to other international similar reports and practice guidelines. METHODS: Chart revision of 425 consecutive admissions (269 patients) for the treatment of manic or mixed episodes (ICD-10 criteria) in a private psychiatric hospital of Belo Horizonte, Brazil, from 1996 to 2000. The rates of utilization of each antimanic medication and ECT were compared to those reported in similar international observational studies (X², bicaudate, alpha =0.05). RESULTS: The observed frequencies of use of each treatment modality were: lithium (71.5%); carbamazepine (34.8%); valproate (9.4%); antipsychotics (83.3%); benzodiazepines (62.4%); antidepressants (7.5%) and ECT (33.2%). The differences detected between local practice and international guidelines were: lower rate of valproate and higher rate of carbamazepine prescription; the use of sine wave devices for ECT; frequent concomitant use of ECT with lithium (72.3%), benzodiazepines (46.8%) and/or carbamazepine (31.2%). CONCLUSION: These results suggest the need to develop national practice guidelines for the treatment of mania and for the use of ECT, and to promote their propagation through specific medical educational programs, aiming at the standardization of practices based on the available scientific evidence.